VRNA

Verona Pharma plc [VRNA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VRNA Stock Summary

Top VRNA Correlated Resources

VRNA

Top 10 Correlated ETFs

VRNA

Top 10 Correlated Stocks

VRNA

In the News

VRNA Financial details

Company Rating
-
Market Cap
1.28B
Income
-54.49M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
79
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-237.1
Forward P/E
-
PEG
70.45
P/S
3122.13
P/B
45.6
P/C
-
P/FCF
-30.07
Quick Ratio
29.61
Current Ratio
30.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.69
EPS next Y
-
EPS next Q
-
EPS this Y
-33.65%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-26.33%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
2.65%
SMA50
5.81%
SMA100
66.61%
Inst Own
-
Inst Trans
-
ROA
-17%
ROE
-19%
ROC
-0.22%
Gross Margin
24%
Oper. Margin
-13351%
Profit Margin
-11067%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
11.83-23.81
52W High
+213.35%
52W Low
+555.18%
RSI
68.55
Rel Volume
3.32
Avg Volume
443.31K
Volume
1.47M
Perf Week
19.98%
Perf Month
13.41%
Perf Quarter
88.91%
Perf Half Y
117.67%
-
-
-
-
Beta
0.415
-
-
Volatility
4.03%, 5.1%
Prev Close
-1.57%
Price
72.07
Change
-2.84%

Something similar

Top by Market Cap
AMZN
CMC.DE
BRH.DE
LLY.DE
FXAIX
Top Correlated ETFs
BBC
CNCR
EZJ
WDNA
EWJ
Top Correlated Stocks
4887.T
RARE
TM
CRNX
PDSB
Similar Market Cap
SVPGLOB.NS
FPIP.ST
SLN
NKRKY
BVH

Company Profile

Healthcare Biotechnology
  • Volume Average 443.31K
  • Market Capitalization 1.28B
  • Employee 79
  • CEO Dr. David S. Zaccardelli Pharm.D.
  • Headquarters London,GB
  • IPO Date 2017-04-28
  • Website https://www.veronapharma.com

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.